Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
NC527-X Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
NC527-X: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BI-3000202 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BI-3000202: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CS-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
CS-101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SHR-9839 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
SHR-9839: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BGT-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BGT-002: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
YH-001 (Yuhong) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
YH-001 (Yuhong): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Zaoboanshen Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Zaoboanshen Granules: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Shuanggen Oral Liquid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Shuanggen Oral Liquid: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tasipimidine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Tasipimidine: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Sanjin Changkang Capsule Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Sanjin Changkang Capsule: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ruanshang Tablets Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Ruanshang Tablets: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Kemaiping granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Kemaiping granules: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.